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Abstract 
Background 
Capsule endoscopy (CE) is mainstream in the evaluation of obscure 
gastrointestinal bleeding (GIB) in the general population. However, the diagnostic 
and therapeutic impact of CE in LVAD patients susceptible to transient bleeding 
remains largely unexplored. This study aimed to assess the benefits of CE in the 
evaluation of LVAD associated GIB.  
Methods 
Retrospective review of patients implanted with a continuous flow LVAD who 
underwent inpatient capsule endoscopy (CE) between January 2014 and May 
2017 at our center.  Identification of lesions with high bleeding potential or 
presence of frank blood were considered abnormal findings on CE study. 
Results 
Twenty-five inpatients who underwent 41 CE were identified. All patients 
presented with GIB and had preceding negative upper endoscopy and 
colonoscopy in the past 4 weeks. On the first capsule in each patient, 19 had 
interpretable images, abnormal findings were detected in 5 patients (high risk 
lesion in 3, frank blood in 2), four of these underwent an enteroscopy and only 2 
 
 
Citation:  Vaidya GN et al. (2017) 
“Capsule Endoscopy in Left 
Ventricular Assist Device Patients: 
Retrospective Review of Efficacy 
and Necessity”. 
The VAD Journal, 3. doi:   
https://doi.org/10.13023/VAD.2017.
11 
 
Editor-in-Chief: Maya Guglin, 
University of Kentucky 
Received: August 2, 2017 
Accepted September 29, 2017 
Published:  September 29, 2017 
© 2017 The Author(s).  This is an 
open access article published 
under the terms of the Creative 
Commons Attribution-
NonCommercial 4.0 International 
License 
(https://creativecommons.org/licens
es/by-nc/4.0/), which permits 
unrestricted non-commercial use, 
distribution, and reproduction in 
any medium, provided that the 
original author(s) and the publication 
source are credited.   
Funding: Not applicable  
Competing interests: Not applicable 
 https://doi.org/10.13023/VAD.2017.11 Page 2 of 12 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
(8%) patients had confirmation of the capsule findings with APC treatment (true 
positive). Excluding patients with malfunction, LVAD interference and poor bowel 
prep, 14 patients had negative/equivocal CE, of which 4 underwent enteroscopy 
due to continued bleeding and 2 of these patients had treatable culprit lesions 
(false negative). A total of 17 (68%) patients were discharged without any 
therapeutic intervention irrespective of the success or findings on CE due to 
clinical stabilization. Twenty patients (80%) had recurrence in a mean 154 days. 
As expected, repeat capsules in the same admission increased the diagnostic 
yield (p=0.031) 
Only nine patients (36%) had capsule-image evidence of reaching the cecum while 
4 patients (16%) had retention which had to be retrieved without further 
complication. 
Conclusions 
This study demonstrated that evaluation of GIB with CE is feasible and safe but 
was associated with a low diagnostic yield and low conversion to therapeutic 
intervention. With a true positive yield of 4% in our cohort, the efficacy and cost-
effectiveness of CE in the LVAD population is debatable. The role of CE in LVAD 
patients may need to be reevaluated.  
An identification of patients who would benefit from a capsule-first approach would 
allow optimum utilization of resources and reduce healthcare expenditure. 
Keywords: Gastrointestinal bleeding, capsule endoscopy, left ventricular assist 
device, advanced heart failure management 
 
Introduction 
Left ventricular assist devices (LVAD) are becoming a progressively more reliable 
and safe long term treatment option for advanced heart failure patients. As the 
cohort of LVAD patients continues to grow, various complications that are 
characteristic of this patient population are becoming evident. Gastrointestinal 
bleeding (GIB) has been reported in up to 20% patients and contributes to 
significant morbidity including multiple hospitalizations, prolonged in patient stay, 
and possibly increased mortality 1,2.  While the number of LVAD patients continues 
to grow, the ideal approach to further evaluation of GIB without an identified 
source on standard evaluation with endoscopy and colonoscopy is unknown. 
Based on guidelines, capsule endoscopy (CE) has been adopted as the procedure 
of choice in general population for evaluation of gastrointestinal bleeding (GIB) 
undiagnosed through upper endoscopy/colonoscopy, especially that estimated to 
originate from the small intestine. While these guidelines have been extrapolated 
to patients with left ventricular assist device (LVAD), the true efficacy and 
therapeutic impact of CE in LVAD patients who are prone to transient but recurrent 
bleeding remains largely unexplored. As the diagnostic and treatment strategies 
evolve, it is important to understand management options for GIB as well as their 
associated limitations. This study aims to assess the necessity of this 
comparatively expensive test through understanding the clinical course of patients 
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after capsule study and identify its role in screening patients for subsequent 
enteroscopy, therapeutic intervention or recurrence prevention. 
Methods  
Study population: 
We performed a retrospective review of patients implanted with a continuous flow 
left ventricular assist device (LVAD) who underwent inpatient capsule endoscopy 
(CE) between January 2014 and May 2017 at our facility- Jewish Hospital, 
Louisville, Kentucky. Appropriate Institutional Review Board exemption was 
obtained.  
Patients were given either one gallon of GoLytely prep split between the night prior 
and morning of the capsule endoscopy study or magnesium citrate prep split with 
two 300 mL bottles night prior to and one 300mL bottle the morning of the capsule 
endoscopy.  Both preps included two tablets of simethicone 80mg the morning of 
the capsule endoscopy study. 
The PillCam SB2 capsule (Given Imaging, Duluth, GA, United States) was 
activated and either swallowed by the patient, or in cases of significant dysphagia 
or delayed gastric emptying, was placed through an upper endoscope directly into 
the duodenum.   
The capsules images were interpreted by certified gastroenterologists. Lesions 
identified on video capsule endoscopy were classified using the P0-P2 system as 
described previously by Saurin, J.C. et al. in 2003 3. Lesions with no bleeding 
potential included P0 lesion such as visible submucosal vasculature, non-specific 
nodules and P1 lesions such as erythema, petechiae or insignificant erosions. 
Lesions with bleeding potential included P2 lesions such as angiodysplasia, ulcers, 
significant erosions or adherent clot. Only studies with P2 lesions or the presence 
of frank bleeding without visualized lesions were considered positive. 
Subsequent single balloon enteroscopy findings and treatments offered were 
noted, confirmation of capsule findings, and treatment with argon plasma 
coagulation (APC) or endoclips were considered ‘true positive’ findings. The 
available data until June 2017 was reviewed on all the patients including 
recurrence and mortality 
Statistical analysis: 
IBM SPSS (version 19.0, SPSS Corp, Chicago, IL, USA) was used for statistical 
analysis. Qualitative data is presented as frequencies and quantitative data as 
mean ± standard deviation. 
Results 
From January 2014 to May 2017, 25 patients had 41 CEs performed.  Of the 41 
studies, 28 capsules were performed in the same admission, while others had 
repeat capsules at 10 days to 7 months for recurrent GIB. Key patient 
demographics are shown in Table 1. LVAD type was Heart Ware in 9 patients 
(36%), HeartMate II in 14 (56%) and HeartMate III in 2 patients (8%). Presenting 
symptoms included melena in 16 patients (64%), hematochezia in 3 (12%), occult 
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bleeding in 6 (24%). Twenty one patients (84%) were on aspirin at presentation 
(six patients on 81mg, 15 on 325mg). All patients were on warfarin with a mean 
INR of 2.54 ± 0.8 on the day of admission.  
Table 1: Key demographics 
 Frequency (%) 
Male gender 19 (76%) 
Hypertension 22 (88%) 
Diabetes 14 (56%) 
Ischemic cardiomyopathy 17 (68%) 
Destination LVAD therapy 18 (72%) 
ICD 23 (92%) 
Ongoing infection 8 (32%) 
Previous GIB 19 (76%) 
ACEinh/ARB use 9 (36%) 
Betablocker 18 (72%) 
Statin 13 (52%) 
PPI 23 (92%) 
 
Capsule was performed 395 ± 467 days after implantation. The capsule 
admissions comprised a 10.7 ± 12.4 days inpatient length of stay and the capsule 
was performed 3.7 ± 2.1 days after admission. All 25 patients had a preceding 
negative upper endoscopy and colonoscopy in the past 4 weeks and 18 patients 
(72%) had them on the same hospital admission.  Mean transit time for the 
capsule was 7.28 ± 1.6 hours. Nine patients (36%) had capsule-image evidence of 
reaching the cecum while 4 patients (16%) had capsule retention which had to be 
retrieved using upper endoscopy (which occurred without further complication). 
While assessing the first capsule endoscopy of each patient, 19 out of 25 patients 
completed their first capsule with interpretable images. Of the remaining 6 
patients, 2 patients had technical malfunction, 2 had LVAD interference with large 
gaps in image acquisition, one had gastric retention, while one had poor bowel 
prep.  The findings are summarized in figure 1.  Of the interpretable 19 CE, 
capsule identified the following lesions: P0 lesion in 2 (8%), P1 lesion in 4 (16%) 
and P2 lesion in 3 (12%) while blood was seen without any mucosal lesion in 2 
(8%) patients.  Of the patients with P2 lesion or identified blood, 4 underwent an 
enteroscopy and only 2 (8%) patients had findings requiring APC treatment, of 
which only 1 (4%) had actual visualization of the capsule lesion and treatment 
(true positive) (Table2). Out of the 14 patients with negative/equivocal CE, 4 
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underwent endoscopy due to continued bleeding and 2 of these patients had 
treatable culprit lesions (false negative) (Table 3).  
 
Figure 1: findings of capsule studies 
*Mucosal P2 lesions included patients 3, 4 and 5 in table 2 
# Findings described in table 3 
 
Table 2. Capsules demonstrating abnormal findings 
Patient Number Capsule lesion Enteroscopy finding Treatment offered 
1 Only blood Oozing from a 
previous biopsy site 
None 
2 Only blood AVM in jejunum APC 
3 Angioectesia in 
proximal small bowel 
AVM in jejunum APC 
4 Adherent clot in 
duodenum 
AVM in jejunum, no 
lesion in duodenum 
APC 
5 Erythematous lesion 
versus ulceration in 
the gastric body  
Not done None 
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Table 3. Endoscopy findings in patients with negative capsules 
Patient  
Number 
Capsule lesion Endoscopy finding Treatment offered 
6 Negative Bleeding AVM in 
jejunum 
APC 
7 Negative Bleeding AVM in 
cecum 
Endoclip 
8 Negative Negative None 
 
9 Negative Negative None 
 
 
Thus a total of 8 out of 25 patients (4 with a CE with abnormal findings and 4 with 
CE with normal finding) underwent enteroscopy post CE, while 17 (68%) patients 
were discharged without any therapeutic intervention irrespective of the finding on 
CE because of clinical stabilization Among patients on higher aspirin dose, the 
dose was reduced or stopped in 6 (33%) at discharge and this was independent of 
the capsule findings. 
Ten patients had >1 CE done, 3 patients had them repeated in the same 
admission, of these 2 had malfunction of the first capsule while 1 had a negative 
first study which prompted a repeat due to continued bleeding. Two of these 
repeated capsules had positive findings. As expected, repeating the capsule in the 
same admission resulted in better diagnostic yield (p=0.031). The CE which 
shortly followed the initial negative study showed blood without a mucosal lesion 
and this prompted an enteroscopy and APC of a jejunal lesion and this patient has 
not had recurrence since.  
Out of the remaining patients with repeat capsules, 2 patients had repeat capsules 
delivered through upper endoscopy in subsequent admissions while 2 patients had 
3 and 4 CE studies each, all of which were negative. The findings are summarized 
in table 4. 
Recurrent GIB was seen in 20 (80%) patients in a mean 154 ± 188 days after the 
first capsule. Of the 5 patients who had bleeding lesions treated in the initial 
admission, 4 had recurrent GIB. Two patients died from non-gastrointestinal 
complications (stroke and intracranial bleeding) 
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Table 4 Findings of first 2 capsules in patients with repeat capsule 
endoscopies 
Patient 
number 
1st Capsule 2nd Capsule Subsequent 
endoscopy findings 
1 No Images- LVAD 
interference 
No images- LVAD 
interference 
Endoclips applied to 
bleeding AVM in 
ascending colon 
2 Technical malfunction Only blood without 
mucosal lesion 
Oozing from previous 
biopsy site 
3 Technical malfunction Only blood without 
mucosal lesion 
APC of AVM in 
jejunum 
4 Gastric retention Negative Not done 
5 Negative Non-bleeding AVM in 
proximal small bowel 
Not done 
6 Negative Colonic AVM APC of bleeding AVM 
in cecum 
7 Negative Negative Not done 
8 Negative Only blood without 
mucosal lesion 
Not done 
9 Negative Negative Not done 
10 Negative Negative  Not done 
 
Discussion 
The purpose of this study was to evaluate a cohort of LVAD patients undergoing 
capsule endoscopy (CE) and assess the impact of this test on the diagnosis, 
treatment and long term outcome of LVAD patients. Here, we present a large and 
well characterized case series of the use of capsule endoscopies to evaluate 
LVAD associated GIB. We found that capsule endoscopy is feasible in LVAD 
patients, but is associated with a high rate of inadequate/incomplete studies.  
While CE often demonstrate abnormal findings, the clinical utility of the abnormal 
findings appears limited. 
With the advent of continuous flow LVAD, the incidence of GIB may be expected 
to rise4, and risk factors for LVAD associated GIB include older age and renal 
dysfunction4. Unlike earlier pulsatile flow LVADs, continuous flow devices require 
the use of antiplatelet medications and warfarin. While the use of antiplatelet 
agents and anticoagulation may contribute to GIB among LVAD patients, several  
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other etiologies for LVAD associated GIB have been identified including acquired 
von Willebrand syndrome and impaired platelet aggregation4.  Additionally, it has 
been proposed that the chronic low pulse pressure caused by continuous flow 
devices leads to local tissue hypoperfusion and dilation of vascular beds causing 
angiodysplasia formation 5. Clinically significant AVMs may occur as early as 2 
months after LVAD implantation and can account for 1/3rd or more of the GIB 
cases2,6. Many such patients may have inaccessible locations of the bleeding or 
oozing from multiple small and transient vascular ectasias within unreachable 
locations of the small intestine. Finding such vague pathological lesions can then 
be challenging, requiring multiple diagnostic and therapeutic procedures. 
Moreover, the treatment of a culprit-looking lesion does not guarantee against 
recurrence in the future, which come more often from new channels of bleeding. 
This can be an ongoing issue for some patients resulting in significant frustration, 
frequent hospitalization, morbidity and sometimes mortality. In such 
circumstances, CE has been adopted as the procedure of choice in evaluation of 
GIB when conventional upper and lower endoscopies are unsuccessful in locating 
the bleeding within their reachable distances. In cases of GIB without a source 
identified on EGD or colonoscopy, visualization of the entire gastrointestinal tract 
including the extent of small intestine with CE or enteroscopy has been 
recommended7. 
After its initial description in 1990s, capsule endoscopy (CE) has become 
mainstream in the evaluation of GIB over the past 20 years, especially in patients 
with occult bleed8,9. The current guidelines recommend the use of CE as the next 
step in evaluation of GIB after conventional upper and lower endoscopies fail to 
ascertain the location of the bleed in the general population4. Studies also 
recommend CE to precede enteroscopy due to its ability to examine the entire 
small intestine in a non-invasive manner4 unless in cases of active bleeding. 
Enteroscopy may then be performed in cases with high suspicion for a small 
intestinal lesion despite a negative CE10. Using an initial CE approach has been 
argued as a means to filter patients who do not need an enteroscopy and thus 
may have favorable long term outcomes11.  
As the capsule travels through the small intestine, it transmits images to a data 
recorder worn by the patient through a radiofrequency channel9. There had been 
concerns about interference with implantable devices utilizing radiofrequency 
channels such as pacemakers/defibrillators as well as possible electromagnetic 
interference with novel technologies such as LVAD9. However, studies have not 
shown any such interference12,13. While there are only few published reports so far, 
the use of CE in LVAD patients appears safe14,15 however the efficacy and cost-
effectiveness profile remains largely unexplored. 
In a study of CE in 30 LVAD patients15, 12 patients were found to have lesions with 
high bleeding potential or frank blood without mucosal lesions on the CE, of which 
50% underwent subsequent procedure. However, the findings of these subsequent 
procedures and hence confirmation of the exact positive findings (true positive) or 
therapeutic interventions performed were not reported in that study. The remaining 
6 patients in that cohort with positive CE had stabilization of that clinical course, so 
no procedure was pursued. Thus positive finding on CE did not guarantee a 
subsequent procedure, a finding similar to our study. In that cohort, the recurrent 
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bleeding rate was 50% among patients with positive CE irrespective of therapeutic 
interventions performed during the index admission. 
There were many differences between the present and the above mentioned study 
with similar number of CE. In our study while the 4 enteroscopies performed in 
patients with an abnormal CEs did identify abnormalities, only 1 patient (4%) was a 
true positive where the CE demonstrated a lesion which was confirmed and 
treated on follow-up enteroscopy while another patient had a lesion treated on 
enteroscopy after CE demonstrated only blood. It is unclear whether the treated 
lesion was the actual source of the visualized blood. The remaining patients with 
abnormal findings on CE had non-treatable lesion on enteroscopy (patient # 1 in 
table 2) or had subsequent clinical stabilization, so no therapeutic intervention was 
offered in that admission despite a seemingly clinically relevant finding (patient #5 
in table 2). In fact, out of the 25 patients, 17 patients (68%) were discharged 
without any therapeutic intervention subsequent to the CE, irrespective of the 
finding of the capsule. 
Irrespective of the CE results and subsequent management, the recurrence rate 
for subsequent GIB was high (80%) over the course of the study period, with the 
first recurrence in a mean of 154 ± 188 days after the first capsule. The low 
diagnostic yield of CE in this study, low conversion rates to therapeutic 
interventions, high subsequent clinical stabilization rates and the significant 
recurrence rate thereafter with absence of direct mortality raises the question of 
whether the CE was necessary in these patients. Performing CE in an inpatient 
setting may prolong the length of stay and with a true positive yield of 4% in our 
cohort of patients, the cost-effectiveness of CE may be debatable.  
Amornsawadwattana et al15 in their above mentioned study reported that the 
capsule did not reach the cecum in only 2 patients and there was no LVAD 
interference with image acquisition with any of the capsules. In the present study 
however, imaging evidence of the capsule reaching cecum was available only in 9 
patients and capsule retention was noted in 4 patients requiring endoscopic 
retrieval which occurred without further complications. Moreover, the yield of CE is 
critically based on the quality of the bowel prep, technical and mechanical success 
of the capsule, lack of interference and most importantly, the clinical stability of the 
patient during the conduct of the study. This significantly restricts the clinical utility 
of the test requiring repeated tests. On the other hand, Sarosiek et al16 reported 
early enteroscopy approach in LVAD patients resulted in less diagnostic tests and 
faster resolution of GIB. However, enteroscopy carries the significant drawback of 
being invasive, resource-intensive, physician supervised, requires sedation and 
possibly anesthetist backup, along with pain and inconvenience for the patient17. 
Also in cases of hidden sources of GIB, CE has been reported to have higher 
detection rates than double balloon enteroscopy in general population18 but this 
has not been evaluated among LVAD patients.  
While the debate for the ideal diagnostic test in obscure GIB rages on in the 
literature, it is also important to consider whether the procedure will provide 
clinically relevant information in a particular patient.  Many such patients may 
simply respond to an outpatient ‘wait and watch’ approach based on the treating 
physician’s clinical assessment15 unless there is clinical deterioration or 
recurrence, in which case a direct enteroscopy approach may be feasible instead. 
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The inability to treat the visualized lesions is a significant drawback of CE17, 
reducing it to a purely diagnostic or screening procedure.  
Also, it is unclear if the higher detection rate with CE translates to higher treatment 
rate in LVAD patients as CE is essentially a diagnostic test which will need a 
procedure such as enteroscopy to treat the identified lesion. In this study, the 
conversion of an abnormal CE finding to a therapeutic enteroscopy was only 2 out 
of 5 (40%), which was not notably different from the conversion of a normal CE to 
a therapeutic enteroscopy (2 out of 4 patients) in the same hospitalization. Despite 
treatment of culprit-looking lesion in 5 patients endoscopically, 4 had recurrent 
GIB. While a past history of previous GIB is a predictor of recurrent bleeding, the 
majority of recurrence is from the same bleeding site1. Identification of such small, 
transient, recurrent culprit-looking lesions on CE may require no further treatment, 
however this needs to be further evaluated.  
The use of capsule in LVAD patients was a safe procedure in our study, without 
any extraneous complications, however capsule retention (4 patients) and LVAD 
interference with image acquisition (2 patients) was reported in some patients. It 
was suggested that the data recorder be placed far from the LVAD to reduce the 
electromagnetic interference9. ICDs are also commonly found in this patient 
population which can also be a rare source of interference with image 
acquisition19. While these issues do not contraindicate the use of capsules in 
LVAD patients, they do suggest judicious use for the highest clinical benefit. 
The limitations of the study included the retrospective design and single facility 
patient selection. The decision to perform CE or subsequent workup based on the 
results of the CE were at the discretion of the GI service.  The study was 
underpowered for statistical analysis of patients with positive capsules or for 
subset analysis of APC treated patients. The site of GIB recurrence was not 
evaluated, unless the patient underwent capsule study again. 
In summary, this study demonstrates low clinical utility of performing CE in LVAD 
patients with GIB without an identified source on EGD and colonoscopy. It also 
highlights the need to closely understand the pathophysiology of GIB in LVAD 
patient and reassess the extrapolation of the diagnostic algorithm involving routine 
CE use from the general population to the LVAD patients. Instead of offering CE to 
all occult GIB cases, identification of the patients who would benefit most from a 
capsule-first approach is necessary for optimum utilization of resources, reduction 
of healthcare expenditure and improvement of quality-adjusted life years through 
expedited discharge. 
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